<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129570">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083276</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1917</org_study_id>
    <secondary_id>2013-002379-17</secondary_id>
    <nct_id>NCT02083276</nct_id>
  </id_info>
  <brief_title>Mecillinam for Treatment of Genital Chlamydia Infection</brief_title>
  <acronym>MecillinamCT</acronym>
  <official_title>Mecillinam for Treatment of Genital Chlamydia Infection in Asymptomatic Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>More and Romsdal Health Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mainstay of treating both symptomatic and asymptomatic genital Chlamydia trachomatis
      infection has been macrolide antibiotics in the form of azithromycin, and alternatively
      tetracycline antibiotics in the form of doxycycline. Studies from the late nineties found a
      single dose of 1 g azithromycin to be equally effective as a 7 day course of 200 mg
      doxycycline a day. However, recent studies have reported increasing treatment failure that
      may indicate that resistance to macrolide antibiotics among Chlamydia trachomatis is
      evolving. Research regarding other bacterial species indicates a high frequency of mutation
      based resistance in conjunction with azithromycin use, i.e. when treating Mycoplasma
      genitalium infections. There has only been case reports of tetracycline resistance among
      human Chlamydia isolates, but a recent study suggest that there might be decreasing
      effectiveness also for doxycycline. Veterinaries has for several years observed increasing
      prevalence of tetracycline resistance among Chlamydia suis. Within the Chlamydia population
      there is promiscuous horizontal gene transfer.

      If the current trend of declining cure rates continues, the investigators might face a
      situation where there are no documented and effective treatments for Chlamydia trachomatis
      infections. This underline an urgent need to expand the number of documented treatment
      options and mecillinam seems to be one of the options that warrant further investigation.

      The objectives of this study is to prove the concept of treating genital Chlamydia
      trachomatis with mecillinam.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Negative control test for Chlamydia in urine (NAAT; Nucleic Acid AmplificationTest)</measure>
    <time_frame>3 weeks after end of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chlamydia Trachomatis Infection</condition>
  <condition>Chlamydial Urethritis</condition>
  <arm_group>
    <arm_group_label>Pivmecillinamhydrochlorid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selexid 400 mg x 3 , 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pivmecillinamhydrochlorid</intervention_name>
    <description>PO 400 mg x3 for 7 days</description>
    <arm_group_label>Pivmecillinamhydrochlorid</arm_group_label>
    <other_name>Selexid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proficient in oral and written Norwegian

          -  Positive NAAT in first void urine for Chlamydia trachomatis

          -  Negative NAAT in first void urine for Mycoplasma genitalium

          -  Heterosexual male

          -  Asymptomatic

        Exclusion Criteria:

          -  Known allergies for mecillinam, penicillin or cephalosporines

          -  Metabolic anomalies of aciduric type

          -  Apparent underweight

          -  Use of mecillinam within the last two months

          -  Under treatment with Valproat, other anti-infective drugs, immuno-modulating
             medication

          -  In the opinion of investigator,obvious reasons why patient will fails to adhere  to
             treatment and follow-up protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Olaug Olsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo UniversityHospital , Olafia Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Olaug Olsen, MD, Phd</last_name>
    <phone>23075840</phone>
    <phone_ext>+47</phone_ext>
    <email>anools@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Einar Nilsen, MD</last_name>
    <phone>71122137</phone>
    <phone_ext>+47</phone_ext>
    <email>einar.nilsen@helse-mr.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Olafia Clinic,Oslo University Hosptial</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Olaug Olsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Olaug Olsen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Chlamydia trachomatis</keyword>
  <keyword>Urethritis</keyword>
  <keyword>Genital Diseases, Male</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Urethritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amdinocillin</mesh_term>
    <mesh_term>Amdinocillin Pivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
